Stocks · Health care · Pharmaceutical Preparations

Lyell Immunopharma, Inc.

LYEL Clue Score29
United States Fiscal year ends December CIK 0001806952 Results filed 4 Nov 2026

What the insiders did Net buying

By person

14 insiders · 33 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
ARCH Venture Fund XIII, L.P. entity
10% owner
$37.50M (2)
—
+$37.50M
2,336,845
$25.17M
—
ARCH Venture Partners IX, LLC entity
10% owner
$37.50M (2)
—
+$37.50M
2,336,845
$25.17M
—
Lynn Seely
President and CEO
—
$353.08K (6)
−$353.08K
63,899
$688.19K
—
Veronica Sanchez Bulis
VP, Corporate Controller
—
$96.91K (6)
−$96.91K
14,799
$159.39K
+56.6%
Gary K. Lee
Chief Scientific Officer
—
$71.69K (6)
−$71.69K
16,220
$174.69K
—
Stephen J. Hill
Chief Operating Officer
—
$51.29K (6)
−$51.29K
16,816
$181.11K
—
David Shook
Chief Medical Officer
—
$31.34K (2)
−$31.34K
20,423
$219.96K
+1,942%
Jarrad Mattieu Aguirre
Chief Medical Officer
—
$3.64K (1)
−$3.64K
19,857
$213.86K
−2.1%
Innovative Cellular Therapeutics Holdings Ltd entity
10% owner
—
$274.30 (2) scheduled
−$274.30
2,818,980
$30.36M
−7.4%
Richard Klausner
Director
—
—
—
843,365
$9.08M
+23.1%
Charles W. Newton
Chief Financial Officer
—
—
—
215,306
$2.32M
—
Sumant Ramachandra
Director
—
—
—
200,000
$2.15M
—
Matthew Lang
Chief Business Officer
—
—
—
162,500
$1.75M
+225.0%
Otis W Brawley
Director
—
—
—
35,640
$383.84K
—

No percentages here. This company's share count has moved by a factor of 15.4 over the window, from 19,211,202 to 295,228,868 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.